Results 21 to 30 of about 47,525 (299)

Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency [PDF]

, 2010
Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency(ORD) present with disordered sex development and glucocorticoid deficiency.
Arlt, Bebia, Chang, de Morais, Dominique Maiter, Dorota Tomalik-Scharte, Fl  ck, Fuhr, Gomes, Hannah E Ivison, Henderson, Jetter, Julia Kirchheiner, Kelley, Kirchheiner, Kranendonk, Nebert, Nicolo, Parkinson, Porter, Ribes, Sachse, Tantcheva-Po  r, Tomalik-Scharte, Uwe Fuhr, Wiebke Arlt   +25 more
core   +2 more sources

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics [PDF]

, 2018
Tamoxifen reduces the rate of breast cancer recurrence by about one-half. It is converted to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome P450 2D6 (CYP2D6) and transported by ATP-binding cassette transporters. Genetic polymorphisms that confer reduced CYP2D6 activity or concurrent use of CYP2D6-inhibiting drugs ...
Cronin-Fenton, Deirdre P, Damkier, Per
openaire   +5 more sources

Pharmacogenetics of analgesic drugs [PDF]

, 2013
• Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R, Cregg, R, Gubbay, A, Russo, G, Sato, H   +4 more
core   +1 more source

Physiology-based IVIVE predictions of tramadol from in vitro metabolism data [PDF]

, 2014
To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and simulation approach (SimcypA (R)).
Allegaert, Karel, Annaert, Pieter, Boussery, Koen, Colin, Pieter, Cuyckens, Filip, Mannens, Geert, Snoeys, Jan, T'jollyn, Huybrecht, Van Bocxlaer, Jan, Van Peer, Achiel, Vermeulen, An   +10 more
core   +1 more source

CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations

Neuropsychiatric Disease and Treatment, 2022
Yong-Hang Li,1,* Wei Huang,1,* Man-Yu Xiao,2 Shi-Qing Huang,1 Hui Chen,1 Zai-Fang Li,1 Xue-Song Li,1 Yong Cheng1,2 1The Third People’s Hospital of Foshan, Foshan, Guangdong, People’s Republic of China; 2Center on Translational Neuroscience ...
Li YH, Huang W, Xiao MY, Huang SQ, Chen H, Li ZF, Li XS, Cheng Y   +7 more
doaj  

Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays [PDF]

, 2010
Copy number variations (CNVs) in the CYP2D6 gene contribute to interindividual variation in drug metabolism. As the most common duplicated allele in Asian populations is the nonfunctional CYP2D6*36 allele, the goal of this study was to identify CNV ...
Flockhart, David A., Hosono, Naoya, Kubo, Michiaki, Nakamura, Yusuke, Ramamoorthy, Anuradha, Skaar, Todd C.   +5 more
core   +1 more source

The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy

Неотложная медицинская помощь, 2020
Relevance. One of the key components of the accelerated recovery protocols (ARP), in addition to minimizing the surgical approach, is an adequate postoperative analgesia.
A. A. Muradyan, D. A. Blagovestnov, D. A. Sychev, P. A. Yartsev, M. L. Rogal, L. N. Kerimova, V. T. Koroshvili, I. A. Yepifanova   +7 more
doaj   +1 more source

CYP2D6 genetic polymorphisms and phenotypes in different ethnicities of Malaysian breast cancer patients [PDF]

, 2016
The cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) is an enzyme that is predominantly involved in the metabolism of tamoxifen. Genetic polymorphisms of the CYP2D6 gene may contribute to inter-individual variability in tamoxifen metabolism,
, Sharifah Noor Akmal, Abdul Rahman, Sabariah, Fee, Wai Chin, Rosli, Rozita, Soon, Choy Chan   +4 more
core   +1 more source

CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis

Терапевтический архив, 2022
Aim. To study the polymorphic markers CYP2D6*4 (G1846A, rs3892097), CYP2D6*6 (T1707del, rs5030655), CYP2D6*10 (C100T, rs1065852), CYP2D6*41 (G2988A, rs28371725) and CYP2D6*3 (A2549del, rs4986774) role in treatment optimization of portal hypertension with
Dmitry A. Sychev, Andrei I. Parusov, Irina D. Loranskaya, Natalia P. Denisenko, Kristina A. Akmalova, Zhannet A. Sozaeva, Olga L. Turkina, Michael S. Zastrozhin   +7 more
doaj   +1 more source

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population

Frontiers in Pharmacology, 2017
Purpose: Asian populations have around 40–60% frequency of reduced function allele CYP2D6∗10 compared to 1–2% in Caucasian populations. The wide range of CYP2D6 enzyme activities in subjects with the CYP2D6∗10 variant is a big concern for clinical ...
Pei Hu, Rui Chen, Xin Zheng
doaj   +1 more source